This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • Eosinophilic Esophagitis
  • /
  • S2k guideline Gastroesophageal reflux disease and ...
Guideline

S2k guideline Gastroesophageal reflux disease and eosinophilic esophagitis of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

S2k guideline Gastroesophageal reflux disease and eosinophilic esophagitis of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)


Scope and purpose:
Gastroesophageal reflux disease is one of the most common organic diseases of the upper abdomen. Although a class of acid inhibitors (proton pump inhibitors, PPI) has fundamentally improved the treatment of many patients since about 1990, a number of unresolved problems remain, such as the diagnostic and therapeutic approach to patients with unsatisfactory symptom control under PPI.

Furthermore, in addition to the annoying symptoms of reflux disease, some patients are at increased risk of developing cancer of the esophagus due to the development of mucosal remodeling in the esophagus (Barrett’s esophagus) [1].

For the reasons mentioned above, the experts consider an update of the guideline to be particularly important. In addition, the guideline will be expanded to include the topic of eosinophilic esophagitis, now the second most common disease of the esophagus, for which there is no guideline in Germany to date.

Target orientation of the guideline:
The goal of the guideline is to be easily applicable in family practice, internal medicine, surgery, pathology, pediatrics, and gastroenterology. In addition, the guideline is intended to provide a corridor of action for common decisions.

Patient target group are patients with gastroesophageal reflux disease or with eosinophilic esophagitis of any age.


Read full Guideline